CTOs on the Move

Versant Media

www.versantmedia.com

 
Versant is an American media and technology company that launched in 2025 as a spin-off from Comcasts NBCUniversal. It focuses on linear television networks and digital assets, distinct from NBCUniversal’s core businesses. The name "Versant" reflects its mission to be adaptable and fluent in media, engaging audiences with premium storytelling, essential news, and live events. The company’s portfolio includes major cable networks such as USA Network, MSNBC, CNBC, E!, Syfy, Oxygen, and Golf Channel. It also holds a 75% stake in Fandango Media, which includes the online movie ticket retailer Fandango and the film review aggregator Rotten Tomatoes, as well as ...
  • Number of Employees: 250-1000
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details

Similar Companies

R A Biel Plumbing and Heating Inc

R A Biel Plumbing and Heating Inc is a Farmington, NM-based company in the Business Services sector.

Armstrong

Armstrong is a Mobile, AL-based company in the Business Services sector.

Nsr

Nsr is a Atlanta, GA-based company in the Business Services sector.

Seed Strategy Inc

Seed Strategy Inc is a Crestview Hls, KY-based company in the Business Services sector.

Mural Oncology

We know that drug development is both an art and a science. The work we do is incredibly technical, intentional, and specific, but there is an art to it - because we must leave room for creativity, innovation and spontaneity. Murals are paintings that transform overlooked or unused spaces - creating something impactful and meaningful. There remains many overlooked opportunities in cancer drug development. This is what inspires us. Our mission is simple, to create novel immunotherapies that can change patients lives so they can get back to what matters most - living. Mural Oncology is leveraging its industry-leading protein engineering platform to revolutionize cytokine-based immunotherapies for the treatment of cancer. Immunotherapies have been transformative for some people living with cancer, but unfortunately many patients still do not benefit - either because they are ineligible for treatment or they do not respond well to current therapies. We leverage our expertise in cytokine biology, immune cell modulation and our protein engineering capabilities to develop first and novel immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective. Mural Oncology is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers. (NASDAQ: MURA)